Rockefeller Capital Management L.P. Has $18.32 Million Holdings in Masimo Co. (NASDAQ:MASI)

Rockefeller Capital Management L.P. raised its position in shares of Masimo Co. (NASDAQ:MASI) by 4.2% in the third quarter, according to its most recent filing with the SEC. The firm owned 137,393 shares of the medical equipment provider’s stock after purchasing an additional 5,541 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Masimo were worth $18,321,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. NBC Securities Inc. increased its position in Masimo by 47.1% during the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 73 shares during the period. GAMMA Investing LLC increased its position in Masimo by 75.0% during the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 111 shares during the period. Northwestern Mutual Wealth Management Co. increased its position in Masimo by 133.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 200 shares during the period. HHM Wealth Advisors LLC boosted its holdings in shares of Masimo by 25.0% during the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock worth $79,000 after buying an additional 125 shares in the last quarter. Finally, Lazard Asset Management LLC boosted its holdings in shares of Masimo by 5,730.0% during the 1st quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock worth $85,000 after buying an additional 573 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Price Performance

Shares of MASI opened at $172.54 on Monday. Masimo Co. has a 12-month low of $91.60 and a 12-month high of $178.27. The business’s fifty day moving average is $149.24 and its 200 day moving average is $129.91. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The stock has a market cap of $9.24 billion, a P/E ratio of 118.99 and a beta of 0.97.

Masimo (NASDAQ:MASI) last issued its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company had revenue of $504.60 million for the quarter, compared to analysts’ expectations of $502.87 million. During the same period last year, the business earned $0.63 EPS. Masimo’s quarterly revenue was up 5.4% compared to the same quarter last year. Sell-side analysts anticipate that Masimo Co. will post 4.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Raymond James upgraded Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price target on the stock in a report on Wednesday, November 6th. Needham & Company LLC restated a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. Piper Sandler increased their price target on Masimo from $165.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. Wells Fargo & Company increased their price target on Masimo from $160.00 to $171.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. Finally, BTIG Research increased their price target on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $167.00.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.